Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06229912 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

StatusRecruiting
PhasePhase 2
Started2024-06-04
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 24 months later Dec 1, 2026 → Dec 1, 2028
See other at-risk trials from M.D. Anderson Cancer Center

Amendment history

2026-09-09
Study Status v8
Primary completion pushed: 2026-12-01 → 2028-12-01
2026-02-16
Study Status v7
Re-verified, no change to tracked fields
2025-10-03
Study Status, Contacts/Locations v6
Study sites1→2
2025-08-12
2 amendments v4-v5
2 re-verifications since 2025-02-13, no change to tracked fields
2025-01-09
Study Status, Study Design v3
Start dateestimated 2024-07-31→confirmed 2024-06-04
Enrollment target15→40
Show 2 earlier versions
2024-06-25
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Study sitesdetails revised at 1 of 1 site
2024-01-30
Study Status, Eligibility v1
Eligibility criteria+1 characters
[...] rt failure (New York Heart Association Classification Class .≥ II), life-threatening, uncontrolled arrhythmia, cerebrovascu [...]
2024-01-18
Original filing
To learn if revumenib (also known as SNDX-5613) can help to control leukemias associated with an increase in expression of HOX genes.
Trial Details
NCT Number NCT06229912
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Syndax Pharmaceuticals
Conditions Leukemia, HOX Gene
Enrollment 40 participants
Start Date 2024-06-04
Primary Completion 2028-12-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-09-11